Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 multiple ascending dose study of intrathecal BIIB132 in adults with spinocerebellar ataxia type 3
NL-OMON51564Phase 1Withdrawn
- Sponsor
- Biogen
- Start
- Jan 2022
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in machado-joseph disease (MJD) comparing BIIB132 multiple ascending dose with Placebo (2 arms). Primary endpoints: Number of participants with adverse events and Number of participants with serious adverse events. Planned start Jan 2022; status: withdrawn.
02
Drugs
BIIB132
03
Conditions
machado-joseph disease (MJD)
Beyond the preview
Go deeper on NL-OMON51564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51564.